Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Mar 26, 2023 8:53pm
375 Views
Post# 35361599

Costs/ profits margins are not part of clinical trial

Costs/ profits margins are not part of clinical trial

A clinical trial has well defined parameters ( 3 pages of patients inclusions & exclusions based on pre trial medical).
Set measurable outcomes. Again very defined measurable.
costs/ profit# & affordability come into play, Within the manufacturers, marketers & of course the medical professionals.
Pelareorep for example. 

1. Is administered IV. Requires no special handling. ...not expensive.
2. Pela has minimal side effects. Requiring little to zero hospitalization for treatments.
3. Inexpensive to make, handle, ship & administer.
so...........should Pelareorep prove efficacy the end use is a no- brainer from a business perspective.

forgot to add:
with the biomarker(s), it can be determined with a simple blood draw if Pela is working or not.
( within 2 weeks).

 

<< Previous
Bullboard Posts
Next >>